Celularity Inc (CELU)vsInsmed Inc (INSM)
CELU
Celularity Inc
$1.21
-4.72%
HEALTHCARE · Cap: $35.18M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1394% more annual revenue ($606.42M vs $40.58M). CELU leads profitability with a -2.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CELU
Avoid19
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
Smaller company, higher risk/reward
ROE of -63.7% — below average capital efficiency
Revenue declined 43.2%
Earnings declined 61.3%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CELU
CELU has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Return on Equity, Revenue Growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
CELU generates stronger free cash flow (-4M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 19/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a leading biotechnology firm focused on transforming the landscape of regenerative medicine through its unique therapeutic cellular products derived from the placenta. With a strong pipeline of next-generation immunotherapies, including allogeneic off-the-shelf solutions, the company aims to enhance treatment efficacy while reducing associated complications for cancer and other serious illnesses. Driven by an experienced leadership team and strategic partnerships, Celularity is well-positioned to address significant unmet medical needs, solidifying its role as a key player in the rapidly evolving field of advanced therapeutics.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?